Editas Medicine, Inc. (EDIT)

Market Cap	100.71M
Revenue (ttm)	61.76M
Net Income (ttm)	-210.57M
Shares Out	82.55M
EPS (ttm)	-2.56
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,223,480
Open	1.260
Previous Close	1.240
Day's Range	1.205 - 1.270
52-Week Range	1.120 - 11.580
Beta	1.94
Analysts	Buy
Price Target	8.08 (+562.3%)
Earnings Date	Feb 26, 2025

About EDIT

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumor...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 3, 2016
• Employees: 265
• Stock Exchange: NASDAQ
• Ticker Symbol: EDIT
• Website: https://www.editasmedicine.com

Financial Performance

In 2023, Editas Medicine's revenue was $78.12 million, an increase of 296.32% compared to the previous year's $19.71 million. Losses were -$153.22 million, -30.49% less than in 2022.

Analyst Forecast

According to 14 analysts, the average rating for EDIT stock is "Buy." The 12-month stock price forecast is $8.08, which is an increase of 562.30% from the latest price.

Price Target

$8.08

(562.30% upside)

Analyst Consensus: Buy